DRI Healthcare Collects $178M from EKTERLY Royalty Put Option
Event summary
- DRI Healthcare received $178M from the exercise of a put option on EKTERLY royalties following Chiesi Group's acquisition of KalVista Pharmaceuticals.
- The transaction was completed on August 11, 2026, terminating DRI Healthcare's royalty participation right in EKTERLY.
- DRI Healthcare exercised the put option on July 10, 2026, after Chiesi Group's acquisition of KalVista Pharmaceuticals.
The big picture
DRI Healthcare's receipt of $178M from the EKTERLY put option underscores its strategy of monetizing pharmaceutical royalties through contractual options. The transaction, completed following Chiesi Group's acquisition of KalVista Pharmaceuticals, highlights the firm's disciplined approach to underwriting and its ability to capitalize on industry consolidation. With over $3 billion deployed across 75+ royalties, DRI Healthcare's move reflects broader trends in pharmaceutical investment, where royalty monetization plays a critical role in portfolio management.
What we're watching
- Deployment Strategy
- How DRI Healthcare will allocate the $178M proceeds to new investment opportunities.
- Market Dynamics
- Whether the completion of this transaction signals a shift in pharmaceutical royalty monetization trends.
- Portfolio Diversification
- The pace at which DRI Healthcare can identify and acquire new royalty participation rights to replace EKTERLY.
Related topics